

A Retrospective Study On Clinical Features Of Early Neonatal Jaundice In Term Babies At Ratchaburi Hospital, Thailand

ABSTRACT

Aims: Neonatal jaundice is the common condition and sometimes it can lead to devastating neurological consequence like kernicterus. This study was aimed to recognize clinical features and to know etiology of term neonatal jaundice.

Study design: Hospital-based retrospective study

Methodology: was conducted by reviewing 117 medical records of neonatal jaundice who were admitted at Ratchaburi Regional Hospital, Bangkok, Thailand from 1st October 2007 to 30th September 2008. Both the patient's and their mother's profiles, etiology and clinical features of jaundice were extracted.

Results: The results showed that female babies were more likely to contract jaundice. The most common etiology was inconclusive jaundice (64.9%) followed by ABO incompatibility (17.9%) and breast feeding jaundice (10.2%). In addition to those, other less common causes were G6PD deficiency, minor blood group incompatibility and cephalhematoma. The onset of the neonatal jaundice usually occurred on the 2nd to the 4th day of life and almost all newborns responded well to phototherapy. Most of interventions were started on the 2nd day of life. Moreover, exchange transfusion was needed in four cases. Maximum microbilirubin and unconjugated bilirubin levels were two factors associated with double side phototherapy and/or exchange transfusion.

Conclusion: As stated by our study, various etiologies of hyperbilirubinemia were found. The most common etiology was inconclusive jaundice which is followed by ABO incompatibility as a second cause but non-immune hemolysis and polycythemia were not discovered in this study. There was significant difference of haematocrit, NRC and reticulocytes between haemolytic and non-haemolytic groups. Detailed approach of history taking and physical examination, early investigations of jaundice work up and septic work up are recommended in eliciting various etiologies and preventing complications.

Keywords: Neonatal jaundice, etiology, clinical feature, retrospective

1. INTRODUCTION

The most common cause of readmission to hospital in healthy term infants is neonatal jaundice [1]. Paediatricians were aggressive in treating jaundice though several factors have changed the management of jaundice [2, 3]. Effective approach and evaluations for management are crucial in preventing bilirubin induced encephalopathy and long term neurodevelopment outcomes [4]. The possible factors exaggerating physiological jaundice were shown in table 1 [5].

26 Table 1: Possible factors exaggerating physiological jaundice

Factor	Clinical correlate
1. Bilirubin load to liver	<ul style="list-style-type: none"> • Infants with polycythemia • Infants of diabetic mother • Collection of extravasated blood like cephalhematoma and intraventricular hemorrhage • Delayed cord clamping
2. Defective uptake from liver	<ul style="list-style-type: none"> • Decreased Y protein due to caloric deprivation
3. Defective bilirubin conjugation	<ul style="list-style-type: none"> • Due to decreased UDPG activity as seen in hypothyroidism and inhibitors in breast milk
4. Decreased hepatic excretion	<ul style="list-style-type: none"> • Congenital infections
5. Inadequate hepatic perfusion	<ul style="list-style-type: none"> • Hypoxia • Congenital heart diseases
6. Increased enterohepatic circulation	<ul style="list-style-type: none"> • Unfed babies • Delayed passage of meconium

27
 28 Studies in the 1980s and 1990s suggested that kernicterus from jaundice was rare and
 29 that too many infants were being treated unnecessarily [6, 7]
 30 Early detection, effective intervention and new approaches to prevention have been also
 31 stimulated as it has a potential damage to developing brain [8]. Previous studies have
 32 indicated a relationship between neonatal hyperbilirubinemia and diverse factors including
 33 racial region, male gender, epidural anaesthesia, and instrumental delivery [9].

- 34
 35 *Risk factors for neonatal hyperbilirubinemia are:*
 36 1. Jaundice visible on the first day of life
 37 2. A sibling of jaundice or anaemia
 38 3. Unrecognized haemolysis (ABO, Rh and other blood incompatibility)
 39 4. Nonoptimal feeding (Formula or breast feeding)
 40 5. Deficiency of glucose 6 phosphate dehydrogenase
 41 6. Infection, Infant of diabetic mother and immaturity
 42 7. Cephalhematoma or bruise, Central haematocrit >65% (polycythemia)
 43 8. East Asian, Mediterranean, Native American heritage [10].

- 44
 45 *Pathological Jaundice fulfils any of the following criteria:*
 46 1. Clinical jaundice appearing in the first 24 hour.
 47 2. Increase on level of total bilirubin by more than 0.5 mg/dL/hr or 5mg/dL/24 hr.
 48 3. Total serum bilirubin > 12 mg/dL in term infants and total serum bilirubin level 10- 14
 49 mg/dL in preterm infants.
 50 4. Direct reacting bilirubin > 2.0 mg/dL [11].

51 The primary concern with respect to exaggerated hyperbilirubinemia is the potential for
 52 neurotoxic effects, but general cellular injury also occurs [12]. Bilirubin can interfere with
 53 neuroexcitatory signals, impair nerve conduction (particularly auditory nerve) inhibit ion
 54 exchange and water transport in renal cells. **Blood brain barrier can be altered and entry to**
 55 **bilirubin to brain** can be affected by infections, acidosis, hypoxia, sepsis, prematurity and
 56 hyperosmolarity [13].

57
 58 Risk factors of severe hyperbilirubinemia: [14]
 59 *Major Risk Factors:*

- 60 1. Pre discharge microbilirubin level in high risk zone
- 61 2. Jaundice observed in 1st 24 hour
- 62 3. Blood group incompatibility with positive direct antiglobulin test, other known haemolytic
- 63 disease
- 64 4. Previous sibling received phototherapy
- 65 5. Cephalhematoma or significant bruising
- 66 6. Exclusive breast feeding if nursing is not going well and weight is excess
- 67 7. East Asian Race

68 *Minor Risk Factors:*

- 69 1. Pre discharge microbilirubinemia level in the high intermediate risk zone
- 70 2. Jaundice observed before discharge
- 71 3. Previous sibling with jaundice
- 72 4. Macrosomic infant of diabetic mother
- 73 5. Male Gender

74 *Decreased risk factors:*

- 75 1. Microbilirubin level in low risk zone
- 76 2. Exclusive bottle feeding
- 77 3. Black race
- 78 4. Discharge from hospital after 72 hour

79

80 Though it is not common of hazardous ($\geq 30\text{mg/dL}$) hyperbilirubinemia, timely
81 recognition, potent work up and compelling management are pivotal roles to prevent chronic,
82 bilirubin-induced neurotoxicity [15]. This study was designed to get a various clinical profiles
83 of early neonatal jaundice. Careful history taking, physical examinations to elicit information
84 on risk factors were recommended for preventing development of pathological jaundice.
85 Moreover, early measurement of serum bilirubin and work up for jaundice were necessary to
86 know different etiologies.

87

88 2. MATERIAL AND METHODS

89

90 This study was a hospital based retrospective record study of 117 medical records,
91 conducted at Ratchaburi regional hospital, Bangkok, Thailand from November 2008 to 2009
92 March. The clinical features of early neonatal jaundiced for newborns younger than 7 days
93 whose gestational age ranges from 37 to 42 weeks were explored and onset of jaundice
94 within 7 days requiring intervention for jaundice was studied. The exclusion criteria included
95 preterm, low birth weights, having major congenital anomalies and congenital infections,
96 systemic infections before onset of jaundice and serious illness including sepsis, meconium
97 aspiration syndrome and severe birth asphyxia.


98 Required data from the selected records were collected and transferred into case record
99 **form forms** that is constructed based upon the variables from Ratchaburi Regional Hospital
100 and study objectives. The data obtained were calculated by SPSS version 11.5 for statistical
101 analysis. The research was funded by the Faculty of Tropical Medicine, Mahidol University,
102 Thailand in collaboration of SEAMEO TROPMED, Thailand.

103

104 3. RESULTS

105

106 Figure 1 shows that inconclusive jaundice was the most common etiology in this study
107 (n=76, 64.9%), which was followed by ABO incompatibility (17.9%). Other diagnoses were
108 breast feeding jaundice (10.2%), G6PD deficiency (4.2%) and minor blood group
109 incompatibility (1.7%). **There was one case of cephalhematoma.** There were no cases of
110 non-immune haemolysis and polycythemia in this study.



111
112
113
114

Figure 1: Etiologies of Jaundice

Table 2: Characteristic maternal profile according to the etiology of jaundice

Maternal profile	No.	Blood group incompatibility		G6PD def. (n=5)	Breast feeding (n=12)	Cephal-hematoma (n=1)	Inconclusive (n=76)
		ABO (n=21)	Minor (n=2)				
Maternal age (n=113)							
15-20 years	26	5	0	0	1	0	20
21-35 years	76	15	2	5	7	0	47
36-45 years	11	1	0	0	4	0	6
Maternal complication (n=116)							
CPD	18	5	0	1	1	0	11
Hypertension	2	0	0	0	0	0	2
Diabetic	1	0	0	0	1	0	0
Hypertension and diabetic	1	0	0	0	0	0	1
No complication	94	16	2	3	10	1	62
Oxytocin using (n=115)							
Yes	3	0	0	0	0	0	3
No	112	21	2	5	11	1	72
Any medication during pregnancy (n=115)							

Yes	2	0	0	0	1	0	1
No	113	21	2	4	11	1	74

Previous neonatal jaundice history (n=67)

Yes	5	0	0	0	1	0	4
No	62	13	0	4	5	1	39

115

116

117

118

119

120

121

122

123

124

Table 2 shows that 47/76 cases (62%) were born from mother aged between 21 to 35 years were diagnosed as inconclusive jaundice. In this study, oxytocin was used in 3 mothers and diagnoses of their infants were inconclusive jaundice. Among 5 cases that had previous history of neonatal jaundice, 1 case was breast feeding jaundice and other 4 cases were inconclusive jaundice. Other findings such as bruise/petechiae, hepatosplenomegaly were not observed in this study.

Table 3: Maximum bilirubin level according to the etiology of jaundice

Maximum bilirubin level	No.	Blood group incompatibility		G6PD def. (n=5)	Breast feeding (n=12)	Cephal-hematoma (n=1)	Inconclusive (n=76)
		ABO (n=21)	Minor (n=2)				
Maximum microbilirubin level (mg/dL)							
<12	5	0	0	0	1	0	4
12-25	106	21	2	5	11	1	66
>25	6	0	0	0	0	0	6
Maximum unconjugated bilirubin level (mg/dL)							
<12	10	1	0	0	1	0	8
12-25	103	20	2	5	11	1	64
>25	4	0	0	0	0	0	4

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Most of the case had the maximum microbilirubin level in range 12-25 mg/dL which a correlate to the result of maximum unconjugated bilirubin level significantly with Pearson coefficient level at 0.699. All cases that had bilirubin level above 25 were in inconclusive etiology. (Table 3)

Table 4 shows that the mean values of CBC profile and bilirubin level according to etiologies were demonstrated. Among mean value of maximum hematocrit (58.3%) was highest in breast feeding jaundice. In all diagnosis, mean value of WBC and platelet count were within normal limit. NRC was found in only ABO incompatibility and inconclusive jaundice and higher mean of NRC in ABO incompatibility (131.5%). Mean of reticulocyte count percentage was 13.6 in minor blood group incompatibility which was the highest in all etiologies. Mean value of conjugated bilirubin was highest (0.7 mg/dL) in ABO incompatibility while as unconjugated was highest in minor blood group incompatibility (17.6 mg/dL). The diagnosis of G6PD deficiency had the highest maximum value of microbilirubin (20.5 mg/dL) among other cause of neonatal jaundice. Only one blood film had hypochromic picture in which was the inconclusive diagnosis. Almost all patients had normal size of red blood cells. Anisocytosis account for 11.9% and microcytes were 3.4%. On the other hand, only 11% of newborns had normal shape of red blood cells. The rest 89% of them had abnormal shape such as poikilocytosis, burr cells, target cells, spherocyte, ovalocyte, schistocyte and polychromasia.

As shown in Table 5, account for all diagnosis, onset of jaundice mostly started on the 2nd day after delivery (n=49; 41.9%). It was followed the 3rd day after birth (n=35; 29.9%) and the 4th day (n=12; 10.3%). Early onsets of jaundice (within 24 hours after birth) were 10 cases

148 (8.5%) and most of them (70%) were inconclusive jaundice. One case of breast feeding
 149 jaundice and 5 cases of inconclusive jaundices presented with late onset of jaundice on the
 150 6th and 7th day of birth. According to onset of jaundice, treatment was started mostly on 2nd
 151 day after birth. Duration of phototherapy was range from 1 to 4 days. There were four cases
 152 need exchange transfusion therapy for rescue. One case was ABO incompatibility which
 153 onset of jaundice on the second day of life, microbilirubin level as 16.4 mg/dL and 14.9%
 154 reticulocyte count observed. Three cases were inconclusive jaundice which onset of
 155 jaundice on the 2nd, the 4th and the 5th day and the microbilirubin level were 38.5, 32.9 and
 156 31.1 mg/dL respectively, without evidence of haemolysis. According to ABO blood group
 157 examination of the mothers and the babies who were diagnosed as ABO incompatibility
 158 (n=11), all blood group O mothers and blood group A and group B in newborn were 10
 159 (47.6%) and 11 (52.4%) respectively.

160 Table 6 shows that the mean value of maximum and minimum haematocrit was lower in
 161 haemolysis group than in non-haemolysis group significantly (P= 0.013 and P<0.001). NRC
 162 count and percent of reticulocyte counts were higher in haemolysis group than in non-
 163 haemolysis group with statistically significant. There were four cases need exchange
 164 transfusion therapy for rescue. One case was ABO incompatibility which onset of jaundice
 165 on the second day of life, microbilirubin level as 16.4 mg/dL on the 1st day after delivery that
 166 compatible with pathological jaundice and reticulocyte count was also increased (14.9%
 167 even on 1st day). Three cases were inconclusive jaundice which onset of jaundice on the
 168 2nd, the 4th and the 5th day and the microbilirubin level are 38.5, 32.9 and 31.1 mg/dL
 169 respectively, without evidence of haemolysis.

170
 171

Table 4: Laboratory profile according to the etiology of jaundice

Laboratory profile (Mean; Range; SD)	Blood group incompatibility		G6PD def. (n=5)	Breast feeding (n=12)	Inconclusive (n=76)
	ABO (n=21)	Minor (n=2)			
CBC profile					
Maximum of Hct (%)	53.1 38-68 (7.3)	54.5 48-61 (9.2)	58.2 52-70 (7.2)	58.3 50-66 (5.9)	56.4 32-70 (6.7)
Minimum of Hct (%)	43.9 31-57 (7.4)	47.5 38-57 (13.4)	51.6 47-63 (6.5)	51.1 38-60 (6.6)	49.9 30-62 (7.1)
WBC count (X10 ³ /mm ³)	14.4 6.9-24.5 (4.7)	14.8 13.9-15.7 (1.3)	11.6 7.8-20.5 (5.1)	13.3 9.1-20.5 (3.6)	15.9 6.0-17.3 (23.3)
Platelet count (X10 ³ /mm ³)	291.0 145-494 (93.6)	345.5 314-377 (44.5)	234.8 165-357 (89.9)	236.3 66-398 (98.7)	275.8 89-599 (84.2)
NRC (/mm ³)	131.5 0-1470 (321.4)	0	0	0	9.9 0-232 (40.5)
% Reticulocyte count	8.6 3-14.9 (3.8)	13.6 3.5-23.6 (14.2)	4.6 2.8-8.0 (2.4)	7.1 0.7-13.4 (4.1)	6.0 0-15.1 (3.4)
Bilirubin					
Conjugated (mg/dL)	0.7 0.2-6.0 (1.2)	0.3 0.3-0.4 (0.0)	0.4 0.2-0.4 (0.1)	0.4 0.2-0.7 (0.2)	0.5 0.0-10.6 (1.2)
Unconjugated (mg/dL)	16.0	17.6	16.6	15.6	16.8

	11.9-21.4 (2.6)	16.4-18.8 (1.7)	12.4-21.1 (3.7)	9.4-19.1 (2.8)	7.3-37.8 (4.9)
Maximum of MB	17.4	18.1	20.5	17.1	18.3
	12.4-24.1 (2.8)	17.5-18.7 (0.8)	17.7-22.2 (1.9)	10.3-21.5 (3.0)	8.9-38.5 (4.9)

172
173
174
175

Table 5: Onset and treatment of neonatal jaundice

Characteristic of jaundice	No.	Blood group incompatibility		G6PD def. (n=5)	Breast feeding (n=12)	Cephal-hematoma (n=1)	Inconclusive (n=76)
		ABO (n=21)	Minor (n=2)				
ONSET OF JAUNDICE							
1 st day of birth	10	2	0	0	1	0	7
2 nd day of birth	49	14	1	4	6	0	24
3 rd day of birth	35	5	0	0	3	1	26
4 th day of birth	12	0	1	1	1	0	9
5 th day of birth	5	0	0	0	0	0	5
6 th day of birth	1	0	0	0	0	0	1
7 th day of birth	5	0	0	0	1	0	4
TREATMENT							
Day of start therapy							
1 st day of birth	10	2	0	0	1	0	7
2 nd day of birth	51	15	2	4	6	0	24
3 rd day of birth	32	3	0	0	3	0	26
4 th day of birth	11	0	0	1	1	0	9
5 th day of birth	4	0	0	0	0	0	4
6 th day of birth	3	1	0	0	0	0	2
7 th day of birth	4	0	0	0	1	0	3
8 th day of birth	2	0	0	0	0	1	1
Phototherapy duration (Days) (Mean; Range; SD)							
Single phototherapy	1.4	1	1.2	1.3	1	1.1	
	0-2		1-2	0-3		0-4	
	(0.6)		(0.4)	(0.9)		(0.7)	
Double phototherapy	0.5	1	0.8	0.3	0	0.5	
	0-2	0-2	0-1	0-1		0-2	
	(0.7)	(1.4)	(0.4)	(0.5)		(0.7)	
All type	1.9	2.0	2.0	1.7	1	1.6	
	1-4	1-3	1-3	1-4		1-6	
	(0.7)	(1.4)	(0.7)	(1.0)		(0.9)	
Exchange transfusion	4	1	0	0	0	0	3

176

Table 6: Laboratory profile according to etiology of jaundice

	Laboratory	Haemolysis (n=24)	Non haemolysis (n=93)	P value
	CBC profile			
181	Maximum of Hct (%)	53.0 38-68 (7.2)	56.8 32-70 (6.5)	0.013
182				
183	Minimum of Hct (%)	44.2 31-57 (7.7)	50.1 30-63 (6.9)	<0.001
184				
185	WBC count (X10 ³ /mm ³)	14.5 6.9-24.5 (4.4)	15.3 6.0-17.3 (21.2)	>0.05
186				
187	Platelet count (X10 ³ /mm ³)	304.1 145-497 (98.1)	265.4 66-599 (83.4)	>0.05
188				
189	NRC count (/mm ³)	115.0 0-1470 (303.0)	8.1 0-232 (36.8)	0.001
190				
191	% Reticulocyte count	8.7 3.0-23.6 (4.9)	6.0 0-15.1 (3.5)	0.003
192	4. Bilirubin			
	Conjugated (m/dL)	0.7 0.16-6.0 (1.2)	0.5 0-10.6 (1.1)	>0.05
	Unconjugated (m/dL)	16.4 11.9-21.4 (2.7)	16.6 7.3-37.8 (4.6)	>0.05
	Maximum of MB	17.6 12.4-24.1 (2.7)	18.2 8.9-38.5 (4.6)	>0.05

193 DISCUSSION

194
195 This study was conducted to describe the various clinical profiles of early neonatal jaundice.
196 **Careful history taking, physical examinations, early measurement of serum bilirubin and**
197 **work up for jaundice to elicit information on risk factors and different etiologies.** According to
198 exclusion criteria of current study, this study fails to illustrate the neonatal jaundice in
199 preterm as the previous study which showed jaundice occurred in 60% of term infants and
200 80% of preterm infants

201 It is crucial to assess characteristic maternal and neonatal profile during hospital stay and
202 on discharge for risk of neonatal jaundice [16].

203 In our study, there was no difference between haemolysis and non-haemolysis group
204 according to spontaneous delivery which was similar to the previous study finding [17].
205 Increased frequency of jaundice is obviously associated with maternal usage of epidural
206 anaesthesia. We found that the minimum haematocrit was significantly lower and

207 reticulocyte count is significantly higher in haemolytic group compare to non-haemolytic
208 group which were compatible with pathogenesis of hyperbilirubinemia. [18].

209 According to etiologies and maternal profile, nearly 50% of ABO incompatibility are
210 primigravida in this study which is similar to the previous study establishing that
211 approximately 50% of the ABO haemolytic jaundice cases occur in first born infants and
212 there is no predictable pattern of recurrent in subsequent infants [19]. Rh haemolytic disease
213 and sepsis are etiologies that have increased risk of bilirubin encephalopathy than ABO
214 incompatibility [20]. Previous research showed inconclusive jaundice was the most common
215 etiology as demonstrated in our study.

216 Theoretically, G6PD deficiency usually occurs in males although heterozygous females
217 may manifest the mild features of disease [21]. In our study, newborns who diagnosed as
218 G6PD deficiency were all males (4.2%) which female with G6PD deficiency could not
219 demonstrate.

220 Infection was one of the risk factor of hyperbilirubinemia [22]. Unexplained unconjugated
221 hyperbilirubinemia may be a first **sign (is it sing or sign)** of neonatal sepsis as bacterial
222 sepsis can contribute to neonatal jaundice [23]. Our study could not demonstrate the higher
223 WBC count in non-haemolytic group compared to haemolytic group. One of the possible
224 explanations was not only infections but also unidentified non-infectious etiologies stands as
225 grounds for non-haemolytic group.

226 Measuring serum bilirubin concentrations exactly 24hours after delivery or at a later time
227 just before discharge may improve the sensitivity of this predictor for hyperbilirubinemia [24].
228 Predictive bilirubin nomogram is an effective predictor for significant hyperbilirubinemia
229 according to their risks, high, intermediate and low [25].

230 Among four cases proceeded exchange transfusion, one case was ABO incompatibility
231 and the rest three cases were inconclusive jaundice. Three cases of inconclusive jaundice
232 denied evidence of haemolysis in which onset of jaundice are on 2nd, 4th and 5th day and
233 the microbilirubin level are 38.5, 32.9 and 31.1 mg/dL respectively. All neonatal jaundice with
234 high bilirubin level would be treated with aggressive treatment (such as exchange
235 transfusion and double side phototherapy) to prevent complication of hyperbilirubinemia [26].
236 In newborn with bilirubin level above 20 mg/dL, there is noticeable association with
237 kernicterus which has 70% long term consequences [27].
238

239 **5. CONCLUSION**

240

241 As stated by our study, various etiologies of hyperbilirubinemia were found. The most
242 common etiology was inconclusive jaundice because it was only rely on medical record. As
243 we know before, the second common etiology was abo incompatibility. Neonatal jaundice
244 caused by non-immune hemolysis and polycythemia were not found in this study. Supporting
245 neonatal sepsis and infections are main concern for neonatal jaundice, wbc count was
246 highest in the inconclusive jaundice. In all diagnosis, mean values of platelet count were
247 within normal limit. Mean value of reticulocyte count was highest in the diagnosis of minor
248 blood group incompatibility. There was significant difference of haematocrit, NRC and
249 reticulocytes between haemolytic and non-haemolytic groups. As the study was the hospital
250 based retrospective record study, the subjective data such as clinical features was not so
251 gained as expected. To retrieve the comprehensive data, the prospective study should be
252 suggested. Nevertheless, the study highlighted the etiologies of neonatal jaundice of study
253 group, demographic data, maternal data and also laboratory profiles, onset and duration of
254 treatments. **(Please the authors should give deductive and logical conclusion that has
255 contribution to knowledge)**

256

257

258 **COMPETING INTERESTS**

259

260 Authors have declared that no competing interests exist.

261

262 **CONSENT**

263

264 NA

265

266 **ETHICAL APPROVAL**

267

268 This research was approved and funded by the Faculty of Tropical Medicine, Mahidol
269 University, Thailand.

270

271 **REFERENCES**

272

- 273 1. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp
274 Med (Lond). 2017; 2; 78(12):699-704. doi: 10.12968/hmed.2017.78.12.699.
- 275 2. Brown AK. Bilirubin metabolism with special reference to neonatal jaundice. Adv
276 Pediatr 1962; 12: 121-87.
- 277 3. Watchko JF, Oksi FA. Bilirubin 20 mg/dl=vagintiphobia. Pediatr. 1983; 71: 660-3.
- 278 4. Olusanya BO, Teeple S, Kassebaum NJ. The Contribution of Neonatal Jaundice to
279 Global Child Mortality: Findings from the GBD 2016 Study. Paediatrics. 2018;
280 141(2). pii: e20171471. doi: 10.1542/peds.2017-1471
- 281 5. Lalitha KG. Neonatal jaundice. In: Ghai OP, Gupta P, Paul VK, editors. Ghai
282 Essential Paediatrics. 5th ed. New Delhi: Interprint; 1993.
- 283 6. Newman AJ, Gross S. Hyperbilirubinemia in breast fed infants. Pediatr 1983;
284 32:995-1000.
- 285 7. Newman TB, Klebanoff MA. Neonatal hyperbilirubinemia and long term outcome.
286 Pediatr. 1993; 92(5):651-7.
- 287 8. Phyllis AD, Daniel SS, David KS. Neonatal hyperbilirubinemia. N Eng J Med. 2001;
288 344(8): 211.

- 289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
9. Campbell N, Harvey D, Norman AP. Increased frequency of neonatal jaundice in a maternity hospital. *Br Med J.* 1976; 1:548-52.
 10. CDC-MMWR (Morbidity and Mortality Weekly Report). Kernicterus in full term infants- United States, 1994- 1998. 2001; 50(23): 491-4.
 11. Anthony JP, Barbara JS. Jaundice and hyperbilirubinemia in newborn. In: Robert MK, Richard EB, Hal BJ, editors. *Nelson Textbook of Pediatrics*. 18th ed. London: WB Saunders; 2007.
 12. Chuniaud L, Dessante M, Chantoux F, Blondeau JP, Francon J, Trivin F. Cytotoxicity of bilirubin for human fibroblasts and rat astrocytes in culture. *Clin Chim Acta.* 2006; 256(2):103-14.
 13. Bratlid D. How bilirubin gets into the brain. *Clin Perinatol.* 1990; 17(2):449-65.
 14. Pamela GL. Jaundice in the Newborn. In: Ronald MP, James DS, Dale AN, editors. *Paediatric hospital medicine, Textbook of inpatient management.* Philadelphia: Lippincott Williams & Wilkins; 2003.
 15. Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, et al. Incidence, Etiology, and Outcomes of Hazardous Hyperbilirubinemia in Newborns. *Paediatrics.* 2014; 134 (3). doi:10.1542/peds.2014-0987
 16. Maisels MJ, Kring E. Length of stay, jaundice and hospital readmission. *Pediatric.* 1998; 101(6): 995-8.
 17. Sarici SU, Yurdakok M, Serdar MA, Oran O, Erdem G, Tekinalp G, et al. An early (sixth hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO haemolytic disease in a selective high risk population of newborns with ABO incompatibility. *Paediatric.* 2002; 109(4); 53.
 18. David E. Neonatal Jaundice. *BMJ Clin Evid.* 2007; 12:319 -28.
 19. Hinkes MT, Cloharty JP. Neonatal hyperbilirubinemia. In: Cloharty JP, Stork AR, editors. *Manual of neonatal care.* 5th ed. Philadelphia: Lippincott Williams & Wilkins; 1998:175-211.
 20. Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, et al. Risk Factors for Neurotoxicity in Newborns With Severe Neonatal Hyperbilirubinemia. *Paediatrics.* 2011; 128(4): e925–e931. doi: [10.1542/peds.2011-0206]
 21. Malcolm IL, David IT, Sunil S. Jaundice. In: Malcolm IL, David IT, Sunil S. editors, *Essential Neonatal Medicine* 4th ed. Oxford: Blackwell Publishing; 2008: 130-41.
 22. Rennie JM, Robertson NRC. Physiological jaundice. In: Rennie JM, Robertson NRC, editors. *A manual of neonatal intensive care.* 4th ed. London, 2002: 419.
 23. Lindar N, Yatsiv I, Tsur M, Matoth I. Unexplained neonatal jaundice as an early diagnostic sign of septicemia in the newborn. *Journal of Perinatology.* 8(4):325-7.
 24. Seidman DS, Shaltiel ZE, Paz I, Gale R. Predicting the Risk of Jaundice in full term Healthy Newborns: A Prospective Population-Based Study. *Journal of Perinatology.* 1999; 19(8): 564-7.
 25. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. *Paediatrics.* 1999; 103(1):6-14.
 26. Tan KL. Neonatal Jaundice. In: Robinson MJ and Lee EL editors. *Paediatric Problems in Tropical Countries.* 2nd ed. London. Dr. K C Chaudhuri Foundation; 1983: 91-8.
 27. Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glick S, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. *Paediatrics.* 2004; 114(1):e130-53.PMID: 15231986.

339 **DEFINITIONS, ACRONYMS, ABBREVIATIONS**
340 Here is the Definitions section. This is an optional section.
341 **Term:** Definition for the term

UNDER PEER REVIEW